Search
NC-531 (Alzhemed, Cerebril)
Indications:
1) Alzheimer's disease (Phase 3 trials, 07/04)
2) hemorrhagic stroke due to cerebral amyloid angiopathy
Dosage:
- 300 mg PO QD [4]
Pharmacokinetics:
-> crosses blood-brain barrier (found in CSF) [1]
Adverse effects:
1) mild, no serious adverse effects noted
2) nausea/vomiting
3) GI distress [4]
Mechanism of action:
1) sulfated glycosaminoglycan mimetic
2) modifies association of Abeta with glycosaminoglycans
3) inhibits amyloid plaque formation
a) binds & diminishes soluble Abeta
b) inhibits Abeta fibrillization
4) may inhibit inflammatory response associated with amyloid plaques
Notes: Neurochem Inc (Canada)
General
miscellaneous pharmacologic agent
References
- Reuters (Georgetown University)
- Geerts H.
NC-531 (Neurochem).
Curr Opin Investig Drugs. 2004 Jan;5(1):95-100. Review.
PMID: 1498398
- http://www.alzforum.org/dis/tre/drc/detail.asp?id=84
- http://www.alzinfo.org/news/11_10.aspx